Unigene Laboratories Inc
(OTCOTHER: UGNE)
| Exchange: | OTCOTHER |
| Stock: | Unigene Laboratories Inc |
| Industry: | Biotechnology |
| Employees: | 57 |
| Unigene Laboratories, Inc. is a biopharmaceutical company. The Company focuses on the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has three operating locations: administrative and regulatory offices in Boonton, New Jersey; a laboratory researches facility in Fairfield, New Jersey, and a pharmaceutical production facility in Boonton, New Jersey. The Company's oral PTH license with GlaxoSmithKline was terminated during the year ended December 31, 2011. Its first product to market is Fortical, a nasal calcitonin product. It is marketed in the United States by Upsher-Smith Laboratories, Inc. (USL) for the treatment of postmenopausal osteoporosis. Other product development programs include oral calcitonin licensed to Tarsa Therapeutics, Inc. (Tarsa), which has completed Phase III testing for the treatment of osteoporosis, and oral parathyroid hormone (PTH), which completed Phase II clinical studies for treatment of osteoporosis. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
